Pioglitazone
3 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
3
Ongoing
0
Recruiting
0
Completed
1
Sites
99
Countries
5
Endpoints
18
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 18 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 2 of 18 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
2
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
3 of 3
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| TOMMORROWBiomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset | Pioglitazone Alzheimer’s disease, MCI / preclinical Alzheimer’s | MMSE ≥25 | Ph 3 | Terminated | 55 | Jul 2018 | 2 | results |
| NCT02284906AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease | Pioglitazone Alzheimer’s disease, MCI / preclinical Alzheimer’s | Age ≥65 | Ph 3 | Terminated | 43 | Jan 2018 | - | results |
| NCT00982202Pioglitazone in Alzheimer Disease | Pioglitazone Alzheimer’s disease | mild-to-moderate AD | Ph 2 | Completed | 2 | Jan 2005 | 4 |
Showing 1-3 of 3 trials